Endostatin (ES), an endogenous angiogenesis inhibitor which has been proven to be effective in inhibiting endothelial cells proliferation, migration and angiogenesis in chorioallantoic membrane, can inhibit the growth and metastasis of tumors by inhibiting angiogenesis around tumor tissue.
Endostatin (ES), an endogenous angiogenesis inhibitor which has been proven to be effective in inhibiting endothelial cells proliferation, migration and angiogenesis in chorioallantoic membrane, can inhibit the growth and metastasis of tumors by inhibiting angiogenesis around tumor tissue. [1] [2] [3] ES can also decrease drug resistance in long term repeating treatment when it is used in combination with other chemotherapeutic agents.
Besides tumor, neovascularization also plays a very important role in several other diseases such as diabetic retinopathy, neovascular age-related macular degeneration, and arthritis. 4) Thus, ES may be useful in the treatment of choroidal neovascularization (CNV) diseases. Recently, inhibition of CNV by intravenous injection of adenoviral vectors expressing ES has been studied, and an encouraging result has been obtained. 4) However, as a protein drug, there are lots of obstacles in clinical use of ES, 5) such as high dose to get its efficacy, 6, 7) short half-life, poor stability, and some other shortcomings just like other protein drugs. Recently, chemical modification of protein has been widely studied in order to overcome these obstacles and improve the effectiveness of these drugs, such as prolonging the half-life, lowering the immunogenicity, and increasing the stability, [8] [9] [10] [11] etc. Currently, the most commonly used modifier is polyethylene glycol (PEG). 12) In our previous study, 8) two ES derivertives low molecular weight heparin-ES (LMWH-ES) and PEG-ES, with higher heat stability and anti-angiogenesis activity in vivo than ES, were prepared. Whether LMWH-ES and PEG-ES were useful in inhibiting endothelial cell proliferation and CNV were concerned. 13) Comparing the antiangiogenesis activity of ES, LMWH-ES and PEG-ES, their effects on endothelial cell proliferation, CNV and zebrafish angiogenesis, 14, 15) as well as on the expression of vascular endothelial growth factor (VEGF) 16) and pigment epithelium derived factor (PEDF) 17) in CNV models, were studied in this paper. In order to identify the difference between ES conjugates and the simple mixture of ES and modifiers, LWMHϩES and PEGϩES were involved in all the experiments as a control.
Fig. 1. Inhibitory Effects of ES, LMWH-ES and PEG-ES on HUVEC Proliferation
The inhibitory activity on HUVEC was assayed by MTT method. Purified ES, LMWH-ES and PEG-ES showed significant inhibitory effects on HUVEC. Significant differences between the inhibition rates of ES and LMWH-ES or PEG-ES groups were observed (pϽ0.05). ES was dissolved in 0.3 mol/l sodium carbonate buffer (pH 9.5) and LMWH activated by periodate oxidation 18) was added, then the solution was agitated slowly in dark at 4°C for 48 h. The reaction was terminated by adding glycine.
MATERIALS AND METHODS

Materials
9)
The solution was subjected to CM-II ion exchange column and Superdex 75 column for chromatography. The eluent containing LMWH-ES was collected, desalted, concentrated and lyophilized.
PEG-6000 was activated by cyanuric chloride. 19) The activated PEG-6000 and ES were dissolved in sodium tetraborate buffer (10 mmol/l, pH 9.0) in a molar ratio of 40 : 1. The reaction was carried out at 4°C under slow agitation. Then, glycine was added to end the reaction. 20) The reaction solution was subjected to CM-II ion exchange column and Superdex 75 column for chromatography purification.
Solvable ES was successfully obtained after expression and purification by ion exchange chromatography and gel filtration chromatography. Two derivatives of ES, LMWH-ES and PEG-ES, were successfully synthesized by chemical modification and separated by gel filtration chromatography.
Cell Proliferation Assay Cell culture was performed as previously described. 21) Human umbilical vein endothelial cells (HUVEC) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated calf serum, 3 ng/ml bFGF, and 1% antibiotics. The inhibitory effect of ES and its modified derivatives on HUVEC proliferation in vitro were assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. 22) The HUVEC in exponential phase were collected and plated in a 96-well plate format at 1.0ϫ10 4 cells/well, in a volume of 200 ml. The cells were incubated at 37°C with humidified 95% air/5% CO 2 . After ES, LMWHϩES, LMWHϪES, PEGϩES, and PEGϪES (5, 10, 15 mg/ml) were added into the wells respectively, cells were incubated for 48 h at 37°C in DMEM media with 10% calf serum. The supernatant was removed and cells were washed with phosphate buffered saline (PBS) twice. After that, the cells were resuspended in DMEM media with 10% calf serum and incubated for 4 h at 37°C with 20 ml of 5 mg/ml MTT solution in each well. After the incubation, the supernatant was removed, 150 ml of dimethyl sulfoxide (DMSO) was added to each well and the plate was agitated for 10 min. Then the absorbance at 570 nm was read, and the inhibitory ratio (IR) was calculated according to the formula below:
IR (%)ϭ(1Ϫabsorbance of experimental group/absorbance of blank control group)ϫ100%
Induction of Choroidal Neovascularization (CNV) and Grouping CNV was generated by modification of a previously described technique. 23) Briefly, four to five week-old male C57BL/6 mice were anesthetized with ketamine (40 mg/kg body weight), and the pupils were dilated with 1% tropicamide. Three burns of krypton laser photocoagulation (50 mm spot size, 0.1-s duration, 150 mW) were delivered to each retina using the slit lamp delivery system and a handheld cover slide as a contact lens. Three burns were performed in the posterior pole of the retina. Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining CNV, so only mice in which a bubble was produced for all four burns were included in the study. (7 d). Samples were solved in PBS with a concentration of 10 mg/ml and were injected into the cavum vitreum with a volume of 1 ml. Protein concentration was measured using Bradford method. 24) Measurement of the Size of Laser-Induced CNV Lesions Three or 7 d after treatment, the size of CNV lesion was evaluated by measuring the area of CNV in choroidal flat mounts. Mice used for the flat-mount technique were anesthetized and perfused with 1 ml of PBS containing 50 mg/ml of fluorescein-labeled dextran as previously described. 4, 25) The eyes were removed and fixed for 1 h in a 10% formalin solution. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. Radial cuts were made from the edge of the eyecup to the equator and the eyecup was flat-mounted in Aquamount with the sclera facing down and the choroid facing up. Flat mounts were examined and images were digitized.
Western Blotting VEGF and PEDF expression of ES, LMWH-ES and PEG-ES groups were detected. Eyes were rapidly removed and fixed in a 10% formalin solution. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. After that, the chorioid tissue was separated from the entire retina and each chorioid tissue was used for western blotting.
Protein extracts were obtained by homogenizing frozen tissues in a pH 7.5 buffer containing 50 mmol/l of Tris, 150 mmol/l of NaCl, 1 mmol/l of ethylenediaminetetraacetic acid (EDTA), 1 mmol/l of Na 3 VO 4 , 1% NP-40, 10% glycerol, 50 mmol/l of NaF and 1 mmol/l of phenylmethyl sulfonylfluoride (PMSF), followed by a centrifugation at 15000 rpm for 20 min. Protein concentration was determined by Bradford method using bovine serum albumin (BSA) as standard. Chorioid tissue extracts (50 mg per lane) were separated via 15% gel electrophoresis and electroblotted onto cellulose nitrate (CN) membranes. Then CN membranes were incubated for 1 h in PBS containing 5% low-fat dry milk and incubated with a primary mouse multiclonal anti-VEGF antibody or anti-PEDF antibody, followed by a secondary horseradish peroxidase (HRP)-conjugated IgG antibody. Subsequently, specific bands were visualized.
Zebrafish Assay Green fluorescent protein (GFP) transgenic zebrafish embryos were maintained at 28°C on a 14 h light/10 h dark cycle. All embryos were generated by natural pair-wise mating and staged as previously described. 26) Four to five pairs were set up for each mating, on average 100-150 embryos per pair were generated. Embryos were maintained in embryo water (5 g of Instant Ocean Salt in 25 l of distilled water, pH 7.4) at 28°C for 20 h until the 21 somite stage before sorting for viability using both morphology and developmental stage as criteria. Healthy embryos were dechorionated by enzymatic digestion with 1 mg/ml protease for 5 min at room temperature.
Samples dissolved in embryo water were transferred into a 96-well plate with 200 ml per well. One healthy embryo at 20 h post-fertilization was added to each well. The 96-well plate was maintained at 28°C on a 14 h light/10 h dark cycle. After incubation for another 52 h, zebrafish were anesthetized by tricaine and the the intersegmental vessels (ISV) were counted. The IR was calculated: IR (%)ϭ(ISV amount of experimental group/ISV amount of blank control)ϫ100%
RESULTS
Eeffects of ES and Its Detivatives on Cell Proliferation
HUVEC proliferation is in a dose dependent manner. Inhibitiory rates of ES at 5 mg/ml, 10 mg/ml and 15 mg/ml were 49.8%, 58.3% and 66.4% respectively. In terms of LMWH-ES, inhibitiory rates were 39.0%, 43.3% and 50.3% at 5 mg/ml, 10 mg/ml and 15 mg/ml, respectively. The inhibitiory rates of PEG-ES were 42.1%, 44.1% and 55.1% at 5 mg/ml, 10 mg/ml and 15 mg/ml, respectively. Curves of LMWHϩES and PEGϩES were not coincide with LMWH-ES and PEG-ES conjugates, respectively (Fig. 1) . Because of the mask effect on the activity domain, LMWH-ES and PEG-ES showed decreased activity on cell proliferation in vitro. , respectively. Just like the results after 3 d, ES and all its derivatives could significantly inhibit CNV (pϽ0.05), and both LMWH-ES and PEG-ES had better effect than ES (pϽ0.05). LMWHϩ ES and PEGϩES can also inhibit CNV, but mixture groups didn't show higher activity compared with its modified one. In all of these groups, PEG-ES showed the best inhibitory activity.
Effect of ES and Its Derivatives on the Size of LaserInduced CNV Lesions
Effects of ES and Its Derivatives on VEGF and PEDF Expression in Choroid Tissue
The VEGF and PEDF expressions in choroid tissue were determined by Western blotting (Fig. 2) . Three days after treatment, compared with control group, ES and its derivatives showed significant downregulating effects on VEGF expression and up-regulating effects on PEDF expression (Fig. 2B ) in choroid tissue. LMWH-ES and PEG-ES showed higher activity in downregulating VEGF expression and up-regulating PEDF expression than ES and PEG-ES indicating the highest activity. Seven days after treatment, the same pattern was shown except that PEG-ES and LMWH-ES showed almost the same activity in down-regulating VEGF expression.
Inhibitory of ES and Its Derivatives on Zebrafish Angiogenesis ES and its derivatives had obvious inhibitory effect on the ISV formation of zebrafish dose-dependently ( Table 2, Fig. 3 ). The IR of ES was 13.2%, 22.2% and 41.7% at 5 mg/ml, 10 mg/ml and 50 mg/ml, respectively. IR of LMWH-ES was 18.9%, 31.5% and 46.8% at 5 mg/ml, 10 mg/ml and 50 mg/ml, respectively, while that of PEG-ES was 18.6%, 34.2% and 49.2% at 5 mg/ml, 10 mg/ml and 50 mg/ml, respectively. PEGϩES mixture group showed almost the same activity compared with ES, but lower activity than PEGϪES group. Both LMWHϩES mixture group and LMWHϪES group showed higher activity compared with ES, and mixture group also showed a lower activity than the modified one LMWH-ES; The results indicated that the two ES derivatives had better effect on blocking new angiogenic and vasculogenic vessels formation than native ES and any other groups, and PEG-ES conjugate performed the highest inhibition on zebrafish angiogenesis.
DISCUSSION
The anti-angiogenic activity of ES is a complex process which results in the inhibition of endothelial cell adhesion, migration and proliferation, as well as in the induction of apoptosis. 1) Most studies on the application of ES in disease treatment involve cancer therapy. However, ES may find its application in the treatment of other diseases, because pathological angiogenesis is also thought to play an important role in several kinds of diseases. Studies have shown that ES is effective in inhibiting corneal neovascularization. 27) But, some disadvantages of ES, such as its high dose to get its efficacy, short half-life and poor stability, limited its clinical use. 5) Chemical modification has been used to improve protein properties for many years. PEG, a modification agent used in many Food and Drug Administration (FDA) approved drugs, is the most commonly used modifier. LMWH, one kind of polysaccharide with anticoagulant, antithrombotic and antiangiogenic activity, was also thought to be a good modifier to improve ES properties.
The results of HUVEC proliferation assay showed that ES and its derivatives could noticeably inhibit cell proliferation and ES showed the highest activity in this experiment. Cause protein activity domain is more or less affected after modification by a modifier, ES derivatives showed lower activity in inhibiting HUVEC proliferation compared with ES, and PEG-ES showed a higher activity than LMWH-ES, which indicated that the modification by PEG caused less activity domain change.
The results of CNV assay showed that PEG-ES indicated the highest activity in inhibiting CNV, while LMWH-ES also showed a higher activity than ES. Chemical modification can prolong the half-life of a protein, [28] [29] [30] and in our previous study, stability of ES was also improved by modification with PEG or LMWH. Although the activity of ES in vitro was higher than that of LMWH-ES and PEG-ES, because of the prolonged half-life and enhanced stability, LMWH-ES and PEG-ES showed higher antiangiogenesis activity in this study. Besides these, the distribution change of PEG-ES or LMWH-ES after intravitreal injection also play very important role in the enhanced anti-angiogenic activity, and it's still under penetrating study.
VEGF is an angiogenesis factor and PEDF is an antiangiogenesis factor, both of which play very important role in angiogenesis. ES could down-regulate VEGF expression and up-regulate PEDF expression, which has been proven in many studies, and it was thought to be one of the important action mechanisms. Does the modification have any effect on this action mechanism of ES? Western blotting result showed that ES, LMWH-ES and PEG-ES all can down-regulate VEGF expression and up-regulate PEDF expression in choroid tissue. The ability order of ES and its derivatives was: PEG-ESϾLMWH-ESϾES, which was just coincide with their anti-angiogenesis activity order. This was thought to be the reason of anti-angiogenesis activity order and 548
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In zebrafish assay, The activity order of ES and its derivatives was: LMWH-ESϾPEG-ESϾES, which was almost same like in CNV assay, and the reason was also thought to be the same as in CNV assay including the longer halflife, enhanced stability and regulation on expression of VEGF and PEDF. In this assay, although the activity of LMWH-ES seems a little higher than that of PEG-ES, they have no significant difference. And this may encourage us to deeply develop LWMH as a novel protein modifier.
Mixture groups (PEGϩES and LMWHϩES) were all included in HUVEC proliferation assay, CNV assay and zebrafish assay. And results showed that mixture group showed lower antiangiogenesis activity in vivo compared with its modified group, which indicated that the higher activity of LMWH-ES and PEG-ES were not obtained by a simple sum of modifier and ES, but the higher stability, longer halflife and co-effects of modifier and ES after the modification.
Although LMWH has anti-angiogenic activity and PEG has none, but LMWH-ES didn't showed higher activity than PEG-ES in all models. The reason was thought to be tightly related to their action mechanisms, which are mainly thought to be the prolonged halflife, enhanced stability, down-regulating VEGF expression and up-regulating PEDF expression. In all these sides, LMWH-ES and PEG-ES showed almost the same effects, so in vitro and in vivo anti-angiogenic activity of LMWH-ES was similar to that of PEG-ES.
In all, ES and its derivatives, LMWH-ES and PEG-ES, can significantly inhibit HUVEC proliferation, CNV and angiogenesis in zebrafish. These results might be useful in making PEG-ES and LMWH-ES potential candidates for anti-angiogenesis drug and enlarging the clinical use of ES and its derivtives in other angiogenesis-related diseases.
